Attached To Cyclopentano-hydrophenanthrene (e.g., Cholesterol, Bile Acid, Steroids, Cholane), Hormone, Or Neurotransmitter, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., T3, T4, Insulin, Human Chorionic Gonadotropin, Intragonadal Regulatory Protein, Mullerian Inhibiting Substance, Inhibin, Epidermal Growth Factor, Nerve Growth Factor, Dopamine, Norepinephrine); Derivative Thereof Patents (Class 424/1.45)
  • Patent number: 10758634
    Abstract: Disclosed are novel compounds, complexes, compositions and methods using Zirconium-89 combined with azamacrocyclic chelators in connection with PET. The compositions and methods should provide better diagnostic, prognostic and therapeutic oncology treatments relative to the presently available chelator compositions due to a variety of superior properties of the disclosed compositions. The present invention also relates to a superior method of making these compounds, complexes, compositions that allows one to make compounds/complexes (and thus, compositions) that were previously unattainable.
    Type: Grant
    Filed: March 18, 2017
    Date of Patent: September 1, 2020
    Assignee: Wake Forest University
    Inventors: Thaddeus J. Wadas, Darpan N. Pandya, Nikunj B. Bhatt
  • Patent number: 10669229
    Abstract: Here described are compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: June 2, 2020
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Joseph E. Payne, John A. Gaudette, Zheng Hou, Victor Knopov, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Yasunobu Tanaka, Violetta Akopian
  • Patent number: 10535434
    Abstract: Presented herein are systems, methods, and apparatus that analyze molecular imprints for detecting cancerous cells. Embodiments of the present disclosure include systems, methods, and apparatus that analyze metabolic imprints of cells for cancer detection. In certain embodiments, the methods/systems comprise extracting thermal and thermodynamic quantities and properties from the molecular imprints. The thermal/thermodynamic quantities and/or further-processed quantities can be mapped on a universal cancer diagnostic scale for disease stratification, thereby providing/determining a normality status of the subject cells.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: January 14, 2020
    Assignee: 4D Path Inc.
    Inventors: Satabhisa Mukhopadhyay, Tathagata Dasgupta, Supratim Guha Ray
  • Patent number: 10117921
    Abstract: The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: November 6, 2018
    Assignee: Zoetis Services LLC
    Inventors: Paul Joseph Dominowski, Dennis L. Foss, Guillermo Gallo, John Morgan Hardham, Richard Lee Krebs, Sandra Ann Marie Lightle, Suman Mahan, Sangita Mediratta, Kaori Mohr, Duncan Mwangi, Sharath K. Rai, Sarah A. Salmon, Shaunak Vora, Lauren Wilmes
  • Patent number: 10100079
    Abstract: The present invention relates to the development of the cationic progesterone compounds as a novel anti-tumor agent. The present invention provides a method for the preparation of novel series of progesterone derivatives. The invention also provides information related to highly selective anti-cancer activities of these compounds in wide range of cancer cell irrespective of their progesterone receptor status. Thus, the presently disclosed cationic progesterone compounds offer a viable option as anti-cancer therapeutics.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: October 16, 2018
    Assignee: Council of Scientific & Industrial Research
    Inventors: Sujan Kumar Mondal, Sudhakar Jinka, Rajkumar Banerjee
  • Patent number: 10087141
    Abstract: [18F]-fluoralkyl tosylates are useful building block for the radiosynthesis of a number of small molecules. A method of purifying [18F]-fluoroalkyl tosylates using an automated radiosynthesis apparatus (e.g. FASTlab module) is described. A method of purifying [18F]-fluoroalky tosylates using a FASTlab module that includes a solid phase extraction (SPE) purification system is described.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: October 2, 2018
    Assignee: GE HEALTHCARE LIMITED
    Inventors: Matthias Eberhard Glaser, Sajinder Luthra, Jane Brown, Robert James Nairne
  • Patent number: 9952300
    Abstract: The present invention generally relates to paramagnetic contrast agents and a Dynamic Contrast Enhanced-MRI method for the non-invasive estimation of the delivery of a macromolecular anticancer drug or pro-drug within pathological tissues and, especially, in solid tumors and for the optimization of anticancer therapies.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: April 24, 2018
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Raffaella Giavazzi, Alessandro Maiocchi, Michele Moschetta, Giovanni Valbusa
  • Patent number: 9234001
    Abstract: The present invention relates to a peptide tag which can be used to bind a Technetium (Tc) or Rhenium (Re) radionuclide to a protein of interest which comprises the peptide tag and allows the imaging of such a tagged protein. In particular the present invention relates to a peptide tag which chelates a Tc or Re atom but which does not comprise a Cysteine residue.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: January 12, 2016
    Assignee: Commissariat a L'Energie Atomique et aux Energies Alternatives
    Inventors: Loïc Le Clainche, Alain Lecoq, Sophie Zinn-Justin, Robert Thai, Michel Masella, Philippe Cuniasse
  • Patent number: 9161720
    Abstract: A sensitive method of assessing treatment using molecular and anatomical imaging scans provides automatic tumor identification and quantification within anatomical zones based on treatment criteria. Absolute or comparative measures of tumors in pre- and/or post-scans are thereby isolated from other tissue to accentuate the progress of the treatment when multiple scattered disease lesions are present.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 20, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Robert Jeraj, Glenn Liu
  • Publication number: 20150104381
    Abstract: The present invention relates to a compound that inhibits the activity of a degrading enzyme for use in combination with a therapeutic or diagnostic compound, preferably a moiety conjugated peptide, in the diagnosis and/or treatment of a disease, in particular cancer, to enhance targeting of the therapeutic or diagnostic compound to the disease site.
    Type: Application
    Filed: July 6, 2012
    Publication date: April 16, 2015
    Applicant: BioSynthema Inc.
    Inventors: Theodosia Maina-Nock, Berthold Artur Nock, Marion de Jong Hendriks
  • Patent number: 8961925
    Abstract: A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the STAT test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate. The test can be administered to a patient having, or suspected of having, Chronic Hepatitis C, Primary Sclerosing Cholangitis (PSC), Non-Alcoholic Fatty Liver Disease (NAFLD), or any chronic liver disease.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: February 24, 2015
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Gregory Thomas Everson, Steve Mark Helmke
  • Publication number: 20150017093
    Abstract: The present invention relates in one aspect to radiolabeled compounds comprising the structure of Formula 1. The radiolabeled compounds are preferably bile acids or bile acid derivatives. Further aspects of the invention relates to use of the compounds comprising the structure of Formula 1 in imaging methods such as for example PET, imaging method using a compound comprising the structure of Formula 1, administering said compound to an individual and making a radiographic image of a region of interest from said individual.
    Type: Application
    Filed: January 29, 2013
    Publication date: January 15, 2015
    Applicants: Aarhus Universitet, Region Midtjylland
    Inventors: Susanne Keiding, Peter Ott, Michael Sorensen, Kim Frisch, Alan Hofmann
  • Publication number: 20140377171
    Abstract: The invention relates to a method of imaging pancreatic ?-cells, endocrine gastroenteropancreatic tumors and bronchial and thyroid neuroendocrine tumors and a method of treating endocrine gastroenteropancreatic tumors and bronchial and thyroid neuroendocrine tumors by targeting of glucose-independent insulinotropic polypeptide receptors (GIP receptors). Compounds considered are GIP or a GIP analog, each carrying a radionuclide, optionally complexed through a chelator. Non-radioactive GIP receptor antagonists as such are also considered in the long-term treatment of the mentioned tumors. The invention also relates to the use of a combination of GIP or a GIP analog, each carrying a radionuclide, with a GLP-1 agonist and/or somatostatin analogs, also carrying a radionuclide.
    Type: Application
    Filed: June 8, 2012
    Publication date: December 25, 2014
    Inventor: Jean Claude Reubi
  • Publication number: 20140314665
    Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 23, 2014
    Applicant: NanoPharmaceuticals LLC
    Inventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
  • Patent number: 8865122
    Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: October 21, 2014
    Assignee: Genentech, Inc.
    Inventors: Herman Gill, Jan Marik, Jeff Tinianow, Simon Williams
  • Patent number: 8778299
    Abstract: The disclosure provides a method for quantification of hepatic function in a subject comprising measuring the clearance of an orally administered isotopically labeled cholic acid in a subject with, or suspected of having or developing, a hepatic disorder, for example, chronic hepatitis C. The disclosure further provides methods and kits for assessment of hepatic function.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: July 15, 2014
    Assignee: The Regents of the University of Colorado, a Body Corporate
    Inventor: Gregory Thomas Everson
  • Publication number: 20140147381
    Abstract: 89Zr radiolabeled somatostatin receptors and other receptors, methods of their making, and method of their using for imaging and treatment of somatostatin receptor bearing tumors and other receptor bearing tumors.
    Type: Application
    Filed: November 29, 2012
    Publication date: May 29, 2014
    Inventor: GREGORY DAVID ESPENAN
  • Patent number: 8680182
    Abstract: The present invention provides methods of promoting the revascularization and/or reenervation of central nervous system lesions using an in-situ crosslinkable hydrogel. The present invention also provides methods of treating a spinal cord injury by topically delivering to the spinal cord injury site a vehicle comprising a neurotrophic factor and/or anti-inflammatory agent. Also provided are methods of treating a spinal cord injury by topically administering or delivering a hydrogel to the injury site.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: March 25, 2014
    Assignees: Clemson University Research Foundation, MUSC Foundation for Research Development
    Inventors: Xing Jin, Xuejun Wen, Vibhor Krishna, Ning Zhang
  • Publication number: 20130272956
    Abstract: The present invention relates to (11?,17?)-11-(4-(2-11C-acetyl)phenyl)-17,23-epoxy-19,24-dinorchola-4,9,20-trien-3-one, an 11C-labelled ORG 33628; a process for the preparation thereof, intermediates used in this process and the use of this compound as a PET tracer for the detection of breast cancer.
    Type: Application
    Filed: June 17, 2011
    Publication date: October 17, 2013
    Inventors: Franciscus Theodorus Leonardus Brands, Johannes Antonius Maria Hamersma, Peter Hermanus Gerardus Wiegerinck
  • Publication number: 20130216475
    Abstract: A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents.
    Type: Application
    Filed: April 2, 2013
    Publication date: August 22, 2013
    Applicant: Genentech, Inc.
    Inventor: Genentech, Inc.
  • Patent number: 8491867
    Abstract: A method of single photon emission computed tomography (SPECT) using dual-isotopes of [99mTc]TRODAT-1 and [123I]ADAM is provided. Through SPECT, anomalies in dopamine and serotonin system are diagnosed with their photos in one examination. Thus, cost and labor for two examinations are saved and uses of SPECT are reduced.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: July 23, 2013
    Assignee: Atomic Energy Council-Institute of Nuclear Energy Research
    Inventors: Kuo-Hsing Ma, Wen-Sheng Huang, Chia-Chieh Chen, Lie-Hang Shen
  • Patent number: 8475765
    Abstract: The present invention relates to a method of producing a hydroxyalkyl starch derivative comprising reacting hydroxyalkyl starch of formula (I) at its reducing end which is not oxidized prior to said reaction, with a compound of formula (II) R?NH—R? (II) wherein R1-R2 and R3 are independently hydrogen or a linear or branched hydroxyalkyl group, and wherein either R? or R? or R? and R? comprise at least one functional group X capable of being reacted with at least one other compound prior to or after the reaction of (I) and (II), as well as to the hydroxyalkyl starch derivative as such, obtainable by said method, and to a pharmaceutical composition comprising said hydroxyalkyl starch derivative.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: July 2, 2013
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Norbert Zander, Harald Conradt, Wolfram Eichner
  • Patent number: 8450097
    Abstract: The application relates to a composition comprising a hyperbranched polymer attached to a core and a biologically active moiety. The biologically active moiety is attached to the core by means of a substantially non-enzymatically cleavable linker L. The composition can be used to deliver the biologically active moiety to its target.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 28, 2013
    Assignee: Ascendis Pharma GmbH
    Inventors: Dirk Vetter, Ulrich Hersel, Harald Rau, Robert Schnepf, Thomas Wegge
  • Patent number: 8444954
    Abstract: New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: May 21, 2013
    Assignee: Bracco Imaging S.p.A.
    Inventors: Enrico Cappelletti, Luciano Lattuada, Karen E. Linder, Edmund Marinelli, Palaniappa Nanjappan, Adrian Nunn, Natarajan Raju, Kondareddiar Ramalingam, Rolf E. Swenson, Michael Tweedle
  • Patent number: 8420053
    Abstract: Improved compounds for use in diagnostic imaging or therapy having the formula M-N-O-P-G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N-O-P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: April 16, 2013
    Assignee: Bracco Imaging S.p.A.
    Inventors: Enrico Cappelletti, Luciano Lattuada, Karen E. Linder, Edmund Marinelli, Palaniappa Nanjappan, Natarajan Raju, Kondareddiar Ramalingam, Rolf E. Swenson, Michael Tweedle
  • Patent number: 8414864
    Abstract: New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N—O—P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy to a patient using the compounds of the invention are also provided. A method for preparing a diagnostic imaging agent from the compound is further provided. A method for preparing a radiotherapeutic agent is further provided.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: April 9, 2013
    Assignee: Bracco Imaging S.p.A.
    Inventors: Enrico Cappelletti, Luciano Lattuada, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Natarajan Raju, Rolf E. Swenson, Michael Tweedle
  • Patent number: 8383081
    Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a carrier such as a polymer, nanoparticle, complex or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing cell death of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: February 26, 2013
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, David M. Goldenberg, Chien-Hsing Chang
  • Patent number: 8367037
    Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: February 5, 2013
    Assignee: Immunomedics, Inc.
    Inventors: John C. Byrd, David M. Goldenberg, Hans J. Hansen
  • Patent number: 8277777
    Abstract: A compound that has affinity with amyloid, exhibits sufficiently rapid clearance from normal tissues, and is suppressed in toxicity such as mutagenicity is provided, which is represented by the following formula (1): or a salt thereof, wherein R1 is a group selected from hydrogen, hydroxyl group, carboxyl group, sulfate group, amino group, nitro group, cyano group, an alkyl substituent with one to 4 carbon atoms or an alkoxy substituent with one to 4 carbon atoms; R2 is a radioactive halogen substituent; and m is an integer of 0 to 2, and a low-toxic diagnostic agent for Alzheimer's disease comprising a compound represented by the above formula or a salt thereof is also provided.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: October 2, 2012
    Assignees: Nihon Medi-Physics Co., Ltd., GE Healthcare Limited
    Inventors: Shigeyuki Tanifuji, Akio Hayashi, Daisaku Nakamura, Shinya Takasaki, Anthony Eamon Storey, Denis Raymond Christophe Bouvet
  • Patent number: 8247375
    Abstract: This invention relates to polypeptides which bind to EGFR family receptors and to applications of those polypeptides in medicine, veterinary medicine, diagnosis diagnostics and imaging.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: August 21, 2012
    Assignee: Affibody AB
    Inventors: Fredrik Nilsson, Tove Eriksson, Andreas Jonsson, Stefan Ståhl, Mikaela Friedman
  • Patent number: 8242081
    Abstract: The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9RALX9RX1LX2RSLX9X3X4X5X6X7X8 (SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: August 14, 2012
    Assignees: Centre National de la Recherche Scientifique, Affymetrix, Inc.
    Inventors: Gilles Divita, Frédéric Heitz, May Catherine Morris, Gudrun Aldrian-Herrada
  • Patent number: 8232251
    Abstract: The invention features compounds of the general formula: B-L-M where B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell; M is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell, and can be a therapeutic moiety or an imaging moiety; and L is a linker coupling B to M. The invention also features methods of use of the compounds in, for example, treating conditions such as viral infections and pain, as well as in labeling nerve cells.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: July 31, 2012
    Assignee: Manzanita Pharmaceuticals, Inc.
    Inventors: G. Craig Hill, Stephen B. Kahl, Robert R. Webb, Constance A. McKee
  • Patent number: 8124051
    Abstract: The present invention relates to compositions and methods for producing a complex drug delivery system which specifically targets cancer cells, has an increase in cellular uptake, is cytotoxic, and suppresses antiapoptotic cellular defenses.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: February 28, 2012
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Tamara Minko, Patrick J. Sinko, Stanley Stein
  • Patent number: 8114381
    Abstract: Positron emitting compounds and methods of their production are provided. The compounds have the formula: (F)m G (R)n wherein each R is a group comprising at least one carbon, nitrogen, phosphorus or sulfur atom and G is joined to R through said carbon, nitrogen, phosphorus or sulfur atom; G is silicon or boron; m is 2 to 5 and n is 1 to 3 with m+n=3 to 6 when G is silicon; m is 1 to 3 and n is 1 to 3 with m+n=3 to 4 when G is boron; and wherein the compound further comprises one or more counterions when the above formula is charged; and wherein at least one F is 18F.
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: February 14, 2012
    Assignee: The University of British Columbia
    Inventors: David M. Perrin, Richard Ting
  • Patent number: 8084015
    Abstract: The present invention provides an immunostimulatory complex specifically adapted to act as adjuvant and as a peptide immunogen stabilizer. The immunostimulatory complex comprises a CpG oligonucleotide and a biologically active peptide immunogen. The immunostimulatory complex is particulate and can efficiently present peptide immunogens to the cells of the immune system to produce an immune response. The immunostimulatory complex may be formulated as a suspension for parenteral administration. The immunostimulatory complex may also be formulated in the form of w/o-emulsions, as a suspension in combination with a mineral salt suspension or with an in-situ gelling polymer for the efficient delivery of an immunogen to the cells of the immune system of a subject following parenteral administration, to produce an immune response which may also be a protective immune response.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: December 27, 2011
    Assignee: United Biomedical, Inc.
    Inventor: Kenneth K. Sokoll
  • Patent number: 8058256
    Abstract: A carrier for delivering small interfering RNA (siRNA) into cells includes a cholesterol residue covalently bonded to oligoarginine. Mixing the siRNA with the carrier produces a complex-containing composition. Contacting a cell with the complex-containing composition results in delivery of the siRNA into the cell. Delivery of an siRNA targeted to vascular endothelial growth factor is a treatment for cancer. Methods of making the carrier and complex are also disclosed.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: November 15, 2011
    Assignee: University of Utah Research Foundation
    Inventors: Won Jong Kim, Sung Wan Kim
  • Patent number: 8021644
    Abstract: The present invention relates to biochemical methods for determining reverse cholesterol transport. Specifically, the rates of the two arms of reverse cholesterol transport (HDL or first arm and post-HDL or second arm) are obtained by measuring the flow of unlabeled cholesterol from tissues into plasma HDL and from plasma HDL to bile acids.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: September 20, 2011
    Assignee: The Regents of the University of California
    Inventor: Marc K. Hellerstein
  • Patent number: 8012481
    Abstract: The present invention relates to the field of neuropathological disorders involving impaired locomotor functions. More specifically, the present invention relates to a composition and method for inducing and restoring locomotor functions, such as basic walking movements in the lower extremities of chronic spinal cord injured animals, such as paraplegic or tetraplegic individuals.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: September 6, 2011
    Assignee: Universite Laval
    Inventor: Pierre Guertin
  • Patent number: 7943581
    Abstract: The present invention concerns cell-penetrating peptides which comprise an amino acid sequence consisting of GLX9WRAX9WRX1LX2RSLX9WX3X4X5X6X7X8(SEQ ID No: 1), wherein X1 is A, L or G, X2 is W or none, X3 is R or K, X4 is K, L or S, X5 is L or K, X6 is R or W, X7 is K or S, and X8 is A, V or Q, and X9 is W, F or Y. These CPPs can be used as vectors for delivering nucleic acids and/or proteins and/or peptides to cells, in vitro or in vivo.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: May 17, 2011
    Assignees: Centre National de laRecherche de la Recherche, AFFYMETRIX, Inc.
    Inventors: Gilles Divita, Frederic Heitz, Catherine May Morris, Gudrun Aldrian-Herrada
  • Patent number: 7939080
    Abstract: There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 108, (b) an isolated and glycosylated polypeptide having from about 300 to 419 amino acids taken from the sequence of SEQ ID NO:2, wherein the C terminal 79 amino acids are present, and wherein at least three N-linked glycosylation sites are present, (c) a monoclonal antibody that binds to the ECD of HER-2, and (d) combinations thereof, with the proviso that the agent cannot be the monoclonal antibody alone, and pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: May 10, 2011
    Assignee: Oregon Health & Science University
    Inventors: Joni K. Doherty, Gail M. Clinton, John P. Adelman
  • Publication number: 20110091376
    Abstract: The invention relates to diagnostic, detection, screening and imaging methods. In various embodiments, methods of diagnosis, detection, screening and imaging include administering a cationic steroid antimicrobial or CSA to a subject having or at risk of having an infection or a hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in an amount effective to diagnose or detect the infection or the hyperproliferative disorder (e.g., a tumor, cancer or neoplasia) in the subject. In a particular aspect, a detectable CSA, namely CSA-13 labeled with 99mTc is used to detect the presence of an infection.
    Type: Application
    Filed: June 16, 2009
    Publication date: April 21, 2011
    Applicant: Brigham Young University
    Inventor: Paul B. Savage
  • Patent number: 7879588
    Abstract: The application relates to a composition comprising a hyperbranched polymer attached to a core and a biologically active moiety. The biologically active moiety is attached to the core by means of a substantially non-enzymatically cleavable linker L. The composition can be used to deliver the biologically active moiety to its target.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: February 1, 2011
    Assignee: Ascendis Pharma A/S
    Inventors: Dirk Vetter, Ulrich Hersel, Harald Rau, Robert Schnepf, Thomas Wegge
  • Publication number: 20100303719
    Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.
    Type: Application
    Filed: January 12, 2009
    Publication date: December 2, 2010
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Sui Huang, John Norton, Daniel Appella, Mark Witschi
  • Patent number: 7815893
    Abstract: The present invention relates to a method of producing a hydroxyalkyl starch derivative comprising reacting hydroxyalkyl starch of formula (I) at its reducing end which is not oxidized prior to said reaction, with a compound of formula (II) R?NH—R? (II) wherein R1-R2 and R3 are independently hydrogen or a linear or branched hydroxyalkyl group, and wherein either R? or R? or R? and R? comprise at least one functional group X capable of being reacted with at least one other compound prior to or after the reaction of (I) and (II), as well as to the hydroxyalkyl starch derivative as such, obtainable by said method, and to a pharmaceutical composition comprising said hydroxyalkyl starch derivative.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: October 19, 2010
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Norbert Zander, Harald S. Conradt, Wolfram Eichner
  • Patent number: 7700542
    Abstract: Polymers comprising a polyethylenimine, a biodegradable group, and a relatively hydrophobic group are useful for the delivery of bioactive agents to cells.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: April 20, 2010
    Assignee: Nitto Denko Corporation
    Inventors: Gang Zhao, Xiaoli Fu, Lei Yu
  • Patent number: 7700559
    Abstract: A compound comprising a gonadotrophin releasing hormone analogue conjugated to a hormone moiety, or a derivative thereof, which is able to bind to a plasma hormone binding protein. The compounds may be used to treat hormone-dependent disorders such as cancer, or as a contraceptive.
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: April 20, 2010
    Assignee: Medical Research Council
    Inventor: Robert Peter Millar
  • Patent number: 7700541
    Abstract: Polymers comprising a polyethylenimine having a molecular weight less than 600 Daltons, a biodegradable group, and a relatively hydrophobic group that are useful for the delivery of bioactive agents to cells.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: April 20, 2010
    Assignee: Nitto Denko Corporation
    Inventors: Yasunobu Tanaka, Gang Zhao, Lei Yu
  • Patent number: 7691405
    Abstract: The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver short interfering nucleic acid (siNA). The compositions described herein are generally referred to as formulated molecular compositions (FMC) or lipid nanoparticles (LNP).
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: April 6, 2010
    Assignee: Sirna Therapeutics, Inc
    Inventors: Tongqian Chen, Kurt Vagle, Chandra Vargeese, Weimin Wang, Ye Zhang
  • Patent number: 7682601
    Abstract: The present invention relates to a chelating agent of the general formula: (I), wherein m is 0 or 1; X is NR4 or S; Y is SR5, NHR5 or P(R5)2; R1 and R3 are the same or different and are selected from H, alkyl or aryl; R2 is H, COOH, NHR6 or (CH2)nCOOR6; R4 is H, alkyl, aryl, (CH2)nCOOR6 or (CH2)nOR6; R5 is H, alkyl, aryl, (CH2)nCOOR6 or (CH2)nOR6, R6 is H, alkyl or aryl; n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and when R1?R3?CH3, R2, R4 and R5 are not all three H. The invention further relates to a method and kit for the preparation of radiolabeled biomolecules while using the chelating agent.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: March 23, 2010
    Assignee: Mallinckrodt Inc.
    Inventors: Isabel Rego Santos, Joao Domingos Galamba Correia, Antonio Manuel Rocha Paulo, Susana Alves, Rute Vitor
  • Patent number: 7666390
    Abstract: The present invention relates to diethylenetriamine pentaacetic acid (DTPA) derivates and metal complexes thereof, and radiation sources and contrast agents including the metal complexes. More particularly, the present invention relates to DTPA derivatives, which contain iodine and are useful as contrast agents for diagnosing renal function, metal complexes of the DTPA derivatives with 99mTc, 166Ho, 111In, 90Y, 153Sm, 186Re, 188Re, 68Ga, or 177Lu, which are useful as liquid radiation sources for treating vascular stenosis and contrast agents for diagnosing renal function, and radiation sources and contrast agents including the metal complexes. The DTPA derivatives and metal complexes thereof are safe because the metal complexes are excreted via the kidneys and bladder within several minutes from the time of use as liquid radiation sources for treating vascular stenosis, and are cost-effective because they are potentially useful as contrast agents and as agents for diagnosing renal function.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: February 23, 2010
    Assignee: Korea Atomic Energy Research Institute
    Inventors: Young-Don Hong, Sun-Ju Choi, Ok Ja Choi